Suchergebnisse - "Kayser, Sabine"

PubPharm (7)

1

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

enthalten in: Journal of hematology & oncology | 2023

von Heitmann, J. | Schlenk, R. | Dörfel, D. | +15

2

Advances in targeted therapy for acute myeloid leukaemia

enthalten in: British journal of haematology | 2018

von Kayser, S. | Levis, M.

3

Midostaurin : a multiple tyrosine kinases inhibitor in acute myeloid leukemia and systemic mastocytosis

enthalten in: Small molecules in hematology | 2018

von Schlenk, R. | Kayser, S.

4

Midostaurin : A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis

enthalten in: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer | 2018

von Schlenk, R. | Kayser, S.

5

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

enthalten in: British journal of haematology | 2015

von Fiedler, W. | Kayser, S. | Kebenko, M. | +13

6

Minimal residual disease-directed therapy in acute myeloid leukemia

enthalten in: Blood | 2015

von Kayser, S. | Schlenk, R. | Grimwade, D. | +2

7

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

enthalten in: Blood | 2011

von Kayser, S. | Döhner, K. | Krauter, J. | +18

1
[1]